These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6085299)

  • 1. The host defense system in the human newborn: the role of interferon and the natural killer cell.
    Read SE; Williams BR
    Clin Invest Med; 1984; 7(4):259-62. PubMed ID: 6085299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The interferon/2-5A synthetase system in primary preleukaemia patients.
    Justesen J; Hokland P; Hokland M
    Prog Clin Biol Res; 1985; 202():439-47. PubMed ID: 3868780
    [No Abstract]   [Full Text] [Related]  

  • 3. [The effect of different types of recombinant interferon on the induction of 2,5-oligoadenylate synthetase in natural killers and the tumor cells in bladder cancer patients].
    Vozianov AF; Drannik GN; Verkhatskaia AA; Zavelevich MP; Prokhnevskaia EL; Verkhatskiĭ PP; Klimenko IA
    Urol Nefrol (Mosk); 1993; (5):22-5. PubMed ID: 7508649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of interferon-gamma in the immunotherapy of neuroblastoma.
    Handgretinger R; Bruchelt G; Daurer B; Lang P; Herter M; Dopfer R; Müller B; Reisfeld RA; Treuner J; Niethammer D
    Prog Clin Biol Res; 1991; 366():401-7. PubMed ID: 1906184
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparative analysis of cord blood and adult lymphocytes: interleukin-2 and interferon production, natural killer cell activity, and lymphocyte populations.
    Kibler R; Hicks MJ; Wright AL; Taussig LM
    Diagn Immunol; 1986; 4(4):201-8. PubMed ID: 2428555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2',5'-oligoadenylate synthetase activity.
    Nielsen B; Hokland M; Justesen J; Hasselbalch H; Ellegaard J; Hokland P
    Eur J Haematol; 1989 Jan; 42(1):50-9. PubMed ID: 2914594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoregulation during acute infection with Epstein-Barr virus: dynamics of interferon and 2',5'-oligoadenylate synthetase activity.
    Brewster FE; Byron KS; Sullivan JL
    J Infect Dis; 1985 Jun; 151(6):1109-15. PubMed ID: 2582067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages.
    Witt PL; Spear GT; Helgeson DO; Lindstrom MJ; Smalley RV; Borden EC
    J Interferon Res; 1990 Aug; 10(4):393-402. PubMed ID: 2121851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell function of human neonatal lymphocytes.
    Uksila J; Lassila O; Hirvonen T
    Clin Exp Immunol; 1982 Jun; 48(3):649-54. PubMed ID: 6180853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Demonstration of 2-5A synthetase in human circulating mononuclear cells after oral administration of an interferon inducer isolated from a fraction of Escherichia coli and Klebsiella pneumoniae].
    Merlin G; Vanderhoven C; Page YM; Falcoff E
    C R Acad Sci III; 1985; 300(17):619-22. PubMed ID: 3939289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha.
    Merritt JA; Borden EC; Ball LA
    J Interferon Res; 1985; 5(1):191-8. PubMed ID: 3989336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo effect of interleukin-2 on the 2',5'-oligoadenylate synthetase activity of peripheral mononuclear blood cells.
    Handgretinger R; Bruchelt G; Kimmig A; Lang P; Daurer B; Dopfer R; Treuner J; Niethammer D
    J Interferon Res; 1990 Feb; 10(1):75-82. PubMed ID: 2109781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenylic; polyuridylic acid.
    Hovanessian AG; Youn JK; Buffet-Janvresse C; Riviere Y; Michelson M; Lacour J; Lacour F
    Cancer; 1985 Jan; 55(2):357-62. PubMed ID: 2578083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ampligen treatment of renal cell carcinoma: changes in 2-5A synthetase, 2-5A oligomer size and natural killer cell activity associated with antitumor response clinically.
    Suhadolnik RJ; Reichenbach NL; Lee C; Strayer DR; Brodsky I; Carter WA
    Prog Clin Biol Res; 1985; 202():449-56. PubMed ID: 3913964
    [No Abstract]   [Full Text] [Related]  

  • 16. Interferon-induced 2-5A synthetase activity in human peripheral blood mononuclear cells after immunization with influenza virus and rubella virus vaccines.
    Penn LJ; Williams BR
    J Virol; 1984 Mar; 49(3):748-53. PubMed ID: 6199512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of natural killer cytotoxicity during childhood: marked increases in number of natural killer cells with adequate cytotoxic abilities during infancy to early childhood.
    Yabuhara A; Kawai H; Komiyama A
    Pediatr Res; 1990 Oct; 28(4):316-22. PubMed ID: 1700360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
    Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
    Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-5A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment.
    Merritt JA; Meltzer DM; Ball LA; Borden EC
    Prog Clin Biol Res; 1985; 202():423-30. PubMed ID: 3832076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro hyporeactivity to alpha-interferon in children with severe combined immunodeficiency disease.
    Williams BR; Read SE; Gelfand EW
    Clin Exp Immunol; 1984 Apr; 56(1):34-8. PubMed ID: 6609035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.